Qure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback